Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Large case series suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than patients with classic mycosis fungoides (MF). However, recent studies described a subgroup of patients with FMF with a more favorable prognosis. Distinction between indolent and aggressive FMF may have important therapeutic consequences but is hampered by the inability of the current tumor-node-metastasis-blood (TNMB) staging system to classify patients with FMF in a clinically meaningful way. OBJECTIVE: To differentiate between indolent and aggressive FMF using clinicopathological criteria and to define prognostic factors in patients with FMF. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study, we followed 203 patients with FMF, included in the Dutch Cutaneous Lymphoma Registry between October 1985 and May 2014 at a tertiary referral center hosting the Dutch Cutaneous Lymphoma Registry. Overall, 220 patients with FMF had been registered, but 17 patients with incomplete follow-up data or a history of classic MF were excluded. MAIN OUTCOMES AND MEASURES: Main outcomes included clinical and histological characteristics, disease progression, and survival. Prognostic factors were investigated using Cox proportional hazard regression analysis. Distinction between early plaque-stage FMF and advanced plaque-stage FMF was made by a blinded review of skin biopsy specimens from patients presenting with plaques. RESULTS: In a cohort of 147 men and 56 women (median [range] age, 59 [15-93] years), patients with histologically early plaque-stage FMF had a very similar overall survival (OS) rate to patients with only patches and/or follicular papules (10-year OS, 71% vs 80%), while the survival rate of patients with histologically advanced plaque-stage FMF was almost identical to that of patients presenting with tumors (10-year OS, 25% vs 27%). Subsequently, 3 clinical subgroups with significantly different survival data were distinguished: early skin-limited FMF (group A; n = 84; 5-year and 10-year OS, 92% and 72%); advanced skin-limited FMF (group B; n = 102; 5-year and 10-year OS, 55% and 28%); and FMF presenting with extracutaneous disease (group C; n = 17; 5-year and 10-year OS, 23% and 2%). Age at diagnosis, large cell transformation and secondary bacterial infection were independent risk factors for disease progression and/or poor survival. CONCLUSIONS AND RELEVANCE: The results of this study provide useful criteria to differentiate between indolent and aggressive FMF and confirm the existence of a subgroup of FMF with a favorable prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Correlation of IL-31 serum levels with severity of atopic dermatitis
Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.05.047 · Cited by 299
Cited by
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019) · Blood · doi:10.1182/blood-2018-11-881268 · Cited by 1,412
Self-citationTrautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Self-citationScarisbrick, J. J., Quaglino, P., Prince, H. M., Papadavid, E., Hodak, E., Bagot, M., Servitje, O., Berti, E., Ortiz‐Romero, P., Stadler, R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17258 · Cited by 244
Self-citationMycosis fungoides: A great imitator
Hodak, E., & Amitay-Laish, I. (2019) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2019.01.004 · Cited by 163
Metadata
- Authors
- van Santen, S., Roach, R. E. J., van Doorn, R., Horváth, B., Bruijn, M. S., Sanders, C. J. G., de Pooter, J. C., van Rossum, M. M., de Haas, E. R. M., Veraart, J. C. J. M., Bekkenk, M. W., Vermeer, M. H., & Willemze, R.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-09-01
- Volume
- 152
- Issue
- 9
- Pages
- 992
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2414200305
- Cited by
- 172
- References
- 3
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.